Compare NHS & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NHS | RPID |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 217.9M | 178.6M |
| IPO Year | N/A | 2021 |
| Metric | NHS | RPID |
|---|---|---|
| Price | $7.46 | $2.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 111.8K | ★ 135.1K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | ★ 13.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,523,000.00 |
| Revenue This Year | N/A | $19.36 |
| Revenue Next Year | N/A | $21.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 16.63 |
| 52 Week Low | $6.95 | $0.87 |
| 52 Week High | $9.17 | $4.50 |
| Indicator | NHS | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 66.84 | 30.10 |
| Support Level | $7.15 | $3.15 |
| Resistance Level | $7.34 | $3.69 |
| Average True Range (ATR) | 0.08 | 0.22 |
| MACD | 0.03 | -0.09 |
| Stochastic Oscillator | 90.91 | 11.72 |
Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.